Literature DB >> 10364287

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.

A D Santin1, P L Hermonat, A Ravaggi, M Chiriva-Internati, D Zhan, S Pecorelli, G P Parham, M J Cannon.   

Abstract

Human papillomavirus (HPV) type 16 (HPV 16) and HPV type 18 (HPV 18) are implicated in the induction and progression of the majority of cervical cancers. Since the E6 and E7 oncoproteins of these viruses are expressed in these lesions, such proteins might be potential tumor-specific targets for immunotherapy. In this report, we demonstrate that recombinant, full-length E7-pulsed autologous dendritic cells (DC) can elicit a specific CD8(+) cytotoxic T-lymphocyte (CTL) response against autologous tumor target cells in three patients with HPV 16- or HPV 18-positive cervical cancer. E7-specific CTL populations expressed strong cytolytic activity against autologous tumor cells, did not lyse autologous concanavalin A-treated lymphoblasts or autologous Epstein-Barr virus-transformed lymphoblastoid cell lines (LCL), and showed low levels of cytotoxicity against natural killer cell-sensitive K562 cells. Cytotoxicity against autologous tumor cells could be significantly blocked by anti-HLA class I (W6/32) and anti-CD11a/LFA-1 antibodies. Phenotypically, all CTL populations were CD3(+)/CD8(+), with variable levels of CD56 expression. CTL induced by E7-pulsed DC were also highly cytotoxic against an allogeneic HLA-A2(+) HPV 16-positive matched cell line (CaSki). In addition, we show that specific lymphoproliferative responses by autologous CD4(+) T cells can also be induced by E7-pulsed autologus DC. E7-specific CD4(+) T cells proliferated in response to E7-pulsed LCL but not unpulsed LCL, and this response could be blocked by anti-HLA class II antibody. Finally, with two-color flow cytometric analysis of intracellular cytokine expression at the single-cell level, a marked Th1-like bias (as determined by the frequency of gamma interferon- and interleukin 4-expressing cells) was observable for both CD8(+) and CD4(+) E7-specific lymphocyte populations. Taken together, these data demonstrate that full-length E7-pulsed DC can induce both E7-specific CD4(+) T-cell proliferative responses and strong CD8(+) CTL responses capable of lysing autologous naturally HPV-infected cancer cells in patients with cervical cancer. These results may have important implications for the treatment of cervical cancer patients with active or adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364287      PMCID: PMC112596     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Functional diversity of the CD8(+) T-cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders.

Authors:  R A Nazaruk; R Rochford; M V Hobbs; M J Cannon
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 2.  Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes.

Authors:  B J Nickoloff; L A Turka
Journal:  Immunol Today       Date:  1994-10

3.  Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix.

Authors:  S Honma; S Tsukada; S Honda; M Nakamura; K Takakuwa; T Maruhashi; S Kodama; K Kanazawa; T Takahashi; K Tanaka
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

4.  Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma.

Authors:  C G Hilders; L Ras; J D van Eendenburg; Y Nooyen; G J Fleuren
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

5.  MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.

Authors:  S Baskar; V Azarenko; E Garcia Marshall; E Hughes; S Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  1994-04-15       Impact factor: 4.868

6.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

Authors:  M E Ressing; A Sette; R M Brandt; J Ruppert; P A Wentworth; M Hartman; C Oseroff; H M Grey; C J Melief; W M Kast
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

8.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

9.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.

Authors:  S Baskar; L Glimcher; N Nabavi; R T Jones; S Ostrand-Rosenberg
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

10.  Proliferating dendritic cell progenitors in human blood.

Authors:  N Romani; S Gruner; D Brang; E Kämpgen; A Lenz; B Trockenbacher; G Konwalinka; P O Fritsch; R M Steinman; G Schuler
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  35 in total

1.  Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

Authors:  Stefania Bellone; Floriana Centritto; Jonathan Black; Carlton Schwab; Diana English; Emiliano Cocco; Salvatore Lopez; Elena Bonazzoli; Federica Predolini; Francesca Ferrari; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-04-27       Impact factor: 5.482

2.  Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.

Authors:  Wen-Fang Cheng; Chien-Nan Lee; Yi-Ning Su; Ming-Cheng Chang; Wen-Chun Hsiao; Chi-An Chen; Chang-Yao Hsieh
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

3.  Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Ken-Yu Lin; Marta Bellone; Paola Todeschini; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Luisa Carrara; Renata Tassi; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2011-07-02       Impact factor: 5.150

4.  Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).

Authors:  Alessandro D Santin; Wei Deng; Michael Frumovitz; Natalia Buza; Stefania Bellone; Warner Huh; Samir Khleif; Heather A Lankes; Elena S Ratner; Roisin E O'Cearbhaill; Amir A Jazaeri; Michael Birrer
Journal:  Gynecol Oncol       Date:  2020-01-07       Impact factor: 5.482

5.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

Review 7.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

Review 8.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

9.  In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

Authors:  K El-Sahwi; S Bellone; E Cocco; M Cargnelutti; F Casagrande; M Bellone; M Abu-Khalaf; N Buza; F A Tavassoli; P Hui; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.

Authors:  A D Santin; S Bellone; A Ravaggi; J J Roman; S Pecorelli; G P Parham; M J Cannon
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.